Kryokonservierung von Erythrozyten mit Hydroxyethylstärke (HES) - Vom Laborversuch zur klinischen Anwendung

Sputtek, Andreas; Horn, Ernst-Peter; Esch, J. Schulte am; Kühnl, P.

doi:10.1055/s-2001-18177

Cited by 7 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FBS free) media with low concentration of permeable cryoprotectant (CPA), such as DMSO [70], [71]. In addition, large molecular weight, non-permeable CPAs such as hydroxyethyl starch also proved beneficial in reducing the cell injury due to water crystallization and intracellular ice formation [72]. The present study demonstrates a cryopreservation method that utilizes media containing xeno-free components with low concentrations of CPA reagents to produce favorable cryopreservation conditions that enabled previously frozen cells to preserve and in vivo exhibit proangiogenic properties such as migration and vascular incorporation.…”

Section: Discussionmentioning

confidence: 99%

MRI Tracking of FePro Labeled Fresh and Cryopreserved Long Term In Vitro Expanded Human Cord Blood AC133+ Endothelial Progenitor Cells in Rat Glioma

et al. 2012

View full text Add to dashboard Cite

BackgroundEndothelial progenitors cells (EPCs) are important for the development of cell therapies for various diseases. However, the major obstacles in developing such therapies are low quantities of EPCs that can be generated from the patient and the lack of adequate non-invasive imaging approach for in vivo monitoring of transplanted cells. The objective of this project was to determine the ability of cord blood (CB) AC133+ EPCs to differentiate, in vitro and in vivo, toward mature endothelial cells (ECs) after long term in vitro expansion and cryopreservation and to use magnetic resonance imaging (MRI) to assess the in vivo migratory potential of ex vivo expanded and cryopreserved CB AC133+ EPCs in an orthotopic glioma rat model.Materials, Methods and ResultsThe primary CB AC133+ EPC culture contained mainly EPCs and long term in vitro conditions facilitated the maintenance of these cells in a state of commitment toward endothelial lineage. At days 15–20 and 25–30 of the primary culture, the cells were labeled with FePro and cryopreserved for a few weeks. Cryopreserved cells were thawed and in vitro differentiated or IV administered to glioma bearing rats. Different groups of rats also received long-term cultured, magnetically labeled fresh EPCs and both groups of animals underwent MRI 7 days after IV administration of EPCs. Fluorescent microscopy showed that in vitro differentiation of EPCs was not affected by FePro labeling and cryopreservation. MRI analysis demonstrated that in vivo accumulation of previously cryopreserved transplanted cells resulted in significantly higher R2 and R2* values indicating a higher rate of migration and incorporation into tumor neovascularization of previously cryopreserved CB AC133+ EPCs to glioma sites, compared to non-cryopreserved cells.ConclusionMagnetically labeled CB EPCs can be in vitro expanded and cryopreserved for future use as MRI probes for monitoring the migration and incorporation to the sites of neovascularization.

show abstract

Section: Discussionmentioning

confidence: 99%

MRI Tracking of FePro Labeled Fresh and Cryopreserved Long Term In Vitro Expanded Human Cord Blood AC133+ Endothelial Progenitor Cells in Rat Glioma

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Although safety concerns have been raised for acute kidney injury and increased risk of mortality when HES is administered to seriously ill patients requiring acute volume resuscitation (particularly to patients with severe sepsis and those in intensive care), [38][39][40][41] HES has extremely low immunogenicity, presumably owing to the common structural features between HES and glycogen, both of which are branched polysaccharides. 42 A good manufacturing practice, high water solubility, tailorability, biocompatibility, biodegradability, and well-dened and proven in vivo safety features not only facilitate HES to be widely applied in clinics as PVE, 36,[43][44][45] cryoprotectant, [46][47][48][49] organ preservation solutions, 50 granulocytes separation solutions, [51][52][53] and cell culture medium, 54 but also to be a promising drug carrier with promising clinical translation potential. [55][56][57] To this end, various drug delivery systems have been recently developed based on HES, including HES and small drug conjugates; [27][28][29][30]32,34,58 HES and protein conjugates; 56,59 HES-derived nanocolloidosomes; 60 and HES-based nanoparticles, [61][62][63][64][65][66][67] capsules, [68][69]…”

Section: Resultsmentioning

confidence: 99%

Colloidal hydroxyethyl starch for tumor-targeted platinum delivery

Xiao

Yang

et al. 2019

Nanoscale Adv.

View full text Add to dashboard Cite

show abstract

“…They subsequently performed a systematic clinical trial in patients [17]. A detailed description of the method for the clinical application can be found in [8], and a review of the development of the procedure in [18]. Nota bene: The patented freezing container ( fig.…”

Section: Cryopreservation With Hydroxyethyl Starchmentioning

confidence: 99%

Cryopreservation of Erythrocytes, Thrombocytes, and Lymphocytes

Sputtek

Kühnl

Rowe

2007

Transfus Med Hemother

View full text Add to dashboard Cite

The cryopreservation of blood cells can be regarded as a classical field of development and application of low temperature biology. Cryopreservation methods have been developed for erythrocytes, which are commonly frozen with glycerol as the cryoprotective additive although hydroxyethyl starch (HES) shows considerable promise. Cryopreserved erythrocytes for transfusion are of advantage in the case of patients with rare blood groups, adverse antibody problems, autologous use and civil as well as military disasters. Additionally they can be used for blood typing, antibody screening and compatibility testing. Cryopreservation methods for thrombocytes, lymphocytes and hematopoietic stem cells usually involve dimethyl sulfoxide (DMSO) as the cryoprotective additive. Low temperature preservation of thrombocytes offers the possibility of making HPA- and/or HLA-typed platelet concentrates available in blood banks at any time. The use of cryopreserved lymphocytes is well established and a routine procedure for clinical laboratory testing. Recently there is a growing clinical interest in cryopreserved lymphocytes in addition to hematopoietic progenitor cells for the supplemental treatment of patients after blood stem cell transplantation. Despite occasional reports, it is our opinion that no clinically suitable method for the preservation of human granulocytes has been developed so far.

show abstract

Kryokonservierung von Erythrozyten mit Hydroxyethylstärke (HES) - Vom Laborversuch zur klinischen Anwendung

Cited by 7 publications

References 3 publications

MRI Tracking of FePro Labeled Fresh and Cryopreserved Long Term In Vitro Expanded Human Cord Blood AC133+ Endothelial Progenitor Cells in Rat Glioma

MRI Tracking of FePro Labeled Fresh and Cryopreserved Long Term In Vitro Expanded Human Cord Blood AC133+ Endothelial Progenitor Cells in Rat Glioma

Colloidal hydroxyethyl starch for tumor-targeted platinum delivery

Cryopreservation of Erythrocytes, Thrombocytes, and Lymphocytes

Contact Info

Product

Resources

About